Beam Global announced an 8% increase in preliminary Q3 2026 revenue compared to the same period last year, driven by strong core business performance and acquisitions. The company is preparing to expand into the drone technology market through its pending acquisition of ScoutDI, a European drone and AI software maker. This move aims to leverage Beam Global's existing capabilities and global footprint to enter commercial, government, and defense drone markets. Full Q3 financial results will be filed by November 16, 2026.
Beam Global's preliminary Q3 2026 revenue growth is 8% year over year. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 13, 2026 22:41 WIB: out of 150 priced US tech stocks, 66 rose and 83 fell. Teradyne Inc. (TER) traded at USD 363.82 with a 5.22% decrease, BigBearai Holdings Inc (BBAI) rose 5.22% to USD 2.42, and Lam Research Corporation (LRCX) dropped 5.18% to USD 293.51.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
